Epizyme, Inc. (EPZM) |
|
1.47 0 (0%)
|
12-31 19:00 |
|
Open: |
1.49 |
Pre. Close: |
1.47 |
|
High:
|
1.4993 |
Low:
|
1.47 |
|
Volume:
|
0 |
Market Cap:
|
0(M) |
|
|
|
Technical analysis |
as of: 2022-11-18 4:20:17 PM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 1.73 One year: 1.75 |
| Support: |
Support1: 1.47 Support2: 1.22 |
| Resistance: |
Resistance1: 1.48 Resistance2: 1.49 |
| Pivot: |
1.47 |
| Moving Average: |
MA(5): 1.47 MA(20): 1.47
MA(100): 1.47 MA(250): 1.47  |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 0 %D(3): 0 |
| RSI: |
RSI(14): 60.7 |
| 52-week: |
High: 3.59 Low: 0.41 |
| Average Vol(K): |
3-Month: 0 (K) 10-Days: 0 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EPZM ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 88 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.5 - 1.51 |
1.51 - 1.52 |
|
Low:
|
1.45 - 1.46 |
1.46 - 1.47 |
|
Close:
|
1.46 - 1.47 |
1.47 - 1.48 |
|
Company Description |
|
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts. As of August 11, 2022, Epizyme, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc.. |
Headline News |
Wed, 27 Sep 2023
Company Announcement - InvestEgate
Fri, 12 Aug 2022
Ipsen completes acquisition of Epizyme expanding its portfolio in ... - Ipsen
Fri, 05 Aug 2022
Ipsen extends expiration date of tender offer for Epizyme, Inc. to 11 ... - Ipsen
Mon, 27 Jun 2022
Ipsen to acquire Epizyme, expanding its portfolio in oncology - Ipsen
Thu, 02 Jun 2022
Epizyme Presents Updates from SYMPHONY-1 Tazemetostat + R2 ... - Business Wire
Tue, 10 May 2022
Epizyme Reports First Quarter 2022 Financial Results and Provides ... - Business Wire
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
104 (M) |
| Shares Float |
133 (M) |
|
% Held by Insiders
|
0.5 (%) |
|
% Held by Institutions
|
90.3 (%) |
|
Shares Short
|
5,490 (K) |
|
Shares Short P.Month
|
10,390 (K) |
Stock Financials |
|
EPS
|
-2.3 |
|
EPS Est Next Qtl
|
-0.68 |
|
EPS Est This Year
|
-2.36 |
|
EPS Est Next Year
|
-2.45 |
|
Book Value (p.s.)
|
1.46 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-582.2 |
|
Return on Assets (ttm)
|
-39 |
|
Return on Equity (ttm)
|
-352.4 |
|
Qtrly Rev. Growth
|
14 |
|
Gross Profit (p.s.)
|
0.17 |
|
Sales Per Share
|
0.37 |
|
EBITDA (p.s.)
|
-2.11 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-210 (M) |
|
Levered Free Cash Flow
|
-112 (M) |
Stock Valuations |
|
PE Ratio
|
-0.65 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
1 |
|
Price to Sales
|
3.96 |
|
Price to Cash Flow
|
-0.73 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
